Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10365713" target="_blank" >RIV/00216208:11150/17:10365713 - isvavai.cz</a>

Alternative codes found

RIV/00179906:_____/17:10365713

Result on the web

<a href="http://www.sciencedirect.com/science/article/pii/S0140673617311911?via%3Dihub" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0140673617311911?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S0140-6736(17)31191-1" target="_blank" >10.1016/S0140-6736(17)31191-1</a>

Result language

angličtina

Original language name

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Original language description

Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis. Randomised, 1 year lasting, double-blinded, placebo-controlled, phase 3 study (LIBERTY AD CHRONOS), adults with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids were enrolled at 161 hospitals, clinics, and academic institutions in 14 countries in Europe, Asia-Pacific, and North America 740 patients. At week 52 patients who received dupilumab achieved EASI-75 in 64% vs 23% with placebo.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

The Lancet

ISSN

0140-6736

e-ISSN

—

Volume of the periodical

389

Issue of the periodical within the volume

10086

Country of publishing house

GB - UNITED KINGDOM

Number of pages

17

Pages from-to

2287-2303

UT code for WoS article

000402872700024

EID of the result in the Scopus database

2-s2.0-85018795523